JP6044154B2 - Medical packaging material - Google Patents

Description

  The present invention relates to a medical packaging material, and more specifically, a medical transparent packaging material comprising a base material layer, a gas barrier layer containing silicon oxide, an ultraviolet absorption layer, and an adhesive layer in this order. About.

  Conventionally, it has been known that some pharmaceuticals and medical devices have photo-degrading properties. In order to preserve them for a long time, a packaging material using an aluminum laminated film excellent in light shielding properties and gas barrier properties has been used (for example, see Patent Document 1).

  However, it is difficult for the packaging material using the aluminum laminated film to distinguish the contents from the outside of the packaging material. For this reason, there is a problem that the packaging material is unsealed for confirmation or the wrong medical package is unsealed, which impairs the preservation of the contents. For example, a press-through package (PTP) is used for packaging pharmaceuticals, and PTP is further packaged with an exterior material using an aluminum laminated film to prevent light deterioration.

  In recent years, pharmacies are managing a vast number of drugs due to the spread of generic drugs. Therefore, the contents cannot be discriminated, and a problem that is difficult to use has occurred.

  For this reason, development of a medical transparent packaging material capable of achieving both prevention of light deterioration of the contents and ensuring the visibility of the contents is eagerly desired.

JP-A-10-264290

  This invention is made | formed in view of said background art, The objective is to provide the medical transparent packaging material which can make the photodegradation prevention of a content, and ensuring the visibility of a content compatible. .

  As a result of intensive studies to solve the above problems, the present inventors have found that a transparent medical packaging has a base material layer, a gas barrier layer containing silicon oxide, an ultraviolet absorbing layer, and an adhesive layer in this order. It has been found that the above-mentioned problems can be solved by containing a specific component in the ultraviolet absorbing layer in the material and controlling the transmittance at a specific wavelength of the medical transparent packaging material. The present invention has been completed based on such findings.

That is, according to one aspect of the present invention,
A transparent packaging material for medical use comprising a base material layer, a gas barrier layer containing silicon oxide, an ultraviolet absorbing layer, and an adhesive layer in this order,
The ultraviolet absorbing layer comprises an ultraviolet absorber and an optical brightener;
The medical transparent packaging material has a light transmittance at a wavelength of 380 nm of 20% or less, a light transmittance at a wavelength of 400 nm of 20% or less, and a light transmittance at a wavelength of 600 nm of 60% or more. A packaging material is provided.

  In the embodiment of the present invention, the medical transparent packaging material has a light transmittance of 380 nm at a wavelength of 7% or less, a light transmittance at a wavelength of 400 nm of 7% or less, and a light transmittance at a wavelength of 600 nm of 70%. More preferably.

In the aspect of the present invention, the water vapor permeability of the medical transparent packaging material is preferably 0.5 g / (m ² · day) or less.

  In an embodiment of the present invention, the ultraviolet absorber is selected from the group consisting of a benzophenone ultraviolet absorber, a benzotriazole ultraviolet absorber, a salicylate ultraviolet absorber, a triazine ultraviolet absorber, and a benzoate ultraviolet absorber. It is preferable that it is at least one kind.

  In the aspect of the present invention, the ultraviolet absorber is preferably a triazine-based ultraviolet absorber.

  In an embodiment of the present invention, the triazine-based ultraviolet absorber is hydroxyphenyl triazine, 2,4-bis [2-hydroxy-4-butoxyphenyl] -6- (2,4-dibutoxyphenyl) -1,3. It is preferably at least one selected from the group consisting of -5-triazine and hydroxyphenyltriazine-based aqueous dispersions.

  In an aspect of the present invention, the fluorescent brightening agent is at least selected from the group consisting of a diaminostilbene fluorescent brightener, a bisstyryl biphenyl fluorescent brightener, and a benzoxazolylthiophene fluorescent brightener. One type is preferable.

  In the aspect of the present invention, it is preferable that the ultraviolet absorbing layer further contains a coloring material.

  In the aspect of the present invention, the gas barrier layer is preferably formed by providing a gas barrier coating film on a silicon oxide vapor deposition film.

  In the aspect of this invention, it is preferable that the said medical transparent packaging material does not contain aluminum metal foil and / or an aluminum vapor deposition film | membrane.

  In the embodiment of the present invention, the medical transparent packaging material is preferably used as a packaging material for pharmaceutical products.

  In the aspect of this invention, it is preferable that the said medical transparent packaging material is used as a packaging material of a medical device.

  In the aspect of this invention, it is preferable that the said medical transparent packaging material is used as a packaging material of pharmaceutical PTP.

  In the embodiment of the present invention, it is preferable that the medical transparent packaging material is used as a packaging material for a liquid preparation.

  In the embodiment of the present invention, the liquid preparation is preferably an infusion bag or a prefilled syringe.

  According to the transparent packaging material for medical use of the present invention, it is possible to achieve both prevention of light deterioration of the contents and visibility of the contents.

It is a schematic cross section which shows an example of the medical transparent packaging material by this invention.

Medical packaging material The medical transparent packaging material according to the present invention comprises a base material layer, a gas barrier layer containing silicon oxide, an ultraviolet absorption layer, and an adhesive layer in this order. The transparent medical packaging material according to the present invention is used as a packaging material for photo-degradable contents such as pharmaceuticals and medical devices. In particular, it is suitably used as a packaging material for liquid preparations such as infusion bags and prefilled syringes, and as a packaging material for PTP for pharmaceuticals. In the present invention, “transparent” is sufficient if it is transparent enough to distinguish contents, and may be translucent.

  In the transparent packaging material for medical use according to the present invention, the light transmittance at a wavelength of 380 nm is 20% or less, preferably 7% or less, more preferably 2% or less. The light transmittance at a wavelength of 400 nm is 20% or less, preferably 7% or less, more preferably 2% or less. The light transmittance at a wavelength of 600 nm is 60% or more, preferably 70% or more, more preferably 80% or more. The medical transparent packaging material according to the present invention satisfies the light transmittance in the above-mentioned range at these specific wavelengths, thereby preventing photodegradation of photodegradable contents such as pharmaceuticals and medical devices and ensuring the visibility of the contents. And both.

The medical transparent packaging material according to the present invention has a water vapor permeability of preferably 0.5 g / (m ² · day) or less, more preferably 0.2 g / (m ² · day) or less, and still more preferably. Is 0.1 g / (m ² · day) or less. The medical transparent packaging material according to the present invention satisfies the above water vapor permeability in the above range, so that the moisture in the liquid preparation evaporates even during the long-term storage of the liquid preparation, and the concentration of the drug in the solution rises above a certain standard. Can be prevented.

  It is preferable that the medical transparent packaging material by this invention does not contain aluminum metal foil and / or an aluminum vapor deposition film in any layer. This is because when an aluminum metal foil and / or an aluminum vapor deposition film is provided, the transmittance of visible light is lowered and the visibility of the contents is deteriorated.

  In FIG. 1, the schematic cross section of an example of the medical transparent packaging material by this invention is shown. The medical transparent packaging material 10 shown in FIG. 1 is formed by laminating a gas barrier layer 30, an ultraviolet absorption layer 40, and an adhesive layer 50 in this order on one surface of a base material layer 20. . Hereinafter, each layer which comprises a medical transparent packaging material is demonstrated.

Base material layer In this invention, although a base material layer is not specifically limited, It is preferable to form using resin which has a moldability and transparency. For example, low density polyethylene, medium density polyethylene, high density polyethylene, linear low density polyethylene, polypropylene, ethylene-vinyl acetate copolymer resin, ionomer resin, ethylene-acrylic acid copolymer resin, ethylene-ethyl acrylate copolymer Copolymer resin, ethylene-methacrylic acid copolymer, ethylene-propylene copolymer, methylpentene resin, polybutene resin, acid-modified polyolefin resin, polyamide resin, polystyrene resin, low crystalline saturated polyester or amorphous It can be formed using a polyester resin or the like. Of these, polyester resins, polybutylene terephthalate resins, polyethylene naphthalate resins, particularly polyethylene terephthalate (PET) resins are preferred because of good moldability and transparency. Usually, the thickness of the base material layer is preferably 4.5 to 100 μm, more preferably 12 to 50 μm, from the viewpoints of moldability and transparency.

Gas Barrier Layer In the present invention, the gas barrier layer contains silicon oxide, and preferably contains a deposited film of silicon oxide. As a method for forming a vapor deposition film, for example, a physical vapor deposition method (Physical Vapor Deposition method, PVD method) such as a vacuum vapor deposition method, a sputtering method, and an ion plating method, or a plasma chemical vapor deposition method, a thermochemical method, or the like. Examples thereof include a chemical vapor deposition method (chemical vapor deposition method, CVD method) such as a vapor phase growth method and a photochemical vapor deposition method.

The deposited film (thin film) of silicon oxide is represented by the general formula: SiO _x (wherein x represents a number from 0 to 2), and the value of x is preferably 1.3 to 1.9. The silicon oxide thin film may be mainly composed of silicon oxide, and may further contain at least one kind of compound composed of one kind of carbon, hydrogen, silicon or oxygen, or two or more kinds of elements by chemical bonding or the like. For example, when a compound having a C—H bond, a compound having a Si—H bond, or a carbon unit is in the form of graphite, diamond, fullerene, or the like, the raw material organosilicon compound or a derivative thereof is further added. It may be contained by a chemical bond or the like. Examples thereof include hydrocarbons having a CH ₃ site, hydrosilica such as SiH ₃ silyl and SiH ₂ silylene, and hydroxyl derivatives such as SiH ₂ OH silanol. As content which said compound contains in the vapor deposition film | membrane of a silicon oxide, it is 0.1-50 mass%, Preferably it is 5-20 mass%. Moreover, when a silicon oxide thin film contains the said compound, it is preferable that content of a compound is reducing toward the depth direction from the surface of the vapor deposition film | membrane of a silicon oxide. As a result, the impact resistance and the like are enhanced by the above compound on the surface of the silicon oxide vapor deposition film, and on the other hand, the vapor deposition of the base material layer and the silicon oxide at the interface with the base material layer due to the low content of the above compound. The tight adhesion with the film becomes strong. The film thickness of the silicon oxide thin film is preferably selected and formed arbitrarily within a range of, for example, about 10 to 3000 mm, particularly about 60 to 1000 mm.

  In the present invention, it is preferable to further provide a barrier coating film on the silicon oxide vapor deposition film in order to enhance the gas barrier property. The gas barrier coating film can be formed by coating with a solution containing at least a water-soluble polymer having a hydroxyl group and alkoxysilane. Examples of the water-soluble polymer having at least a hydroxyl group include polyvinyl alcohol, polyvinyl pyrrolidone, starch, methyl cellulose, carboxymethyl cellulose, sodium alginate, an ethylene-vinyl alcohol copolymer, and the like. Polyvinyl alcohol is preferred. These resins may be commercially available. For example, as an ethylene / vinyl alcohol copolymer, Kuraray Co., Ltd., Eval EP-F101 (ethylene content: 32 mol%), Nippon Synthetic Chemical Industry Co., Ltd., Soarnol D2908 (ethylene content; 29 mol%) and the like can be used. Moreover, as polyvinyl alcohol, RS-110 (degree of saponification = 99%, degree of polymerization = 1,000) manufactured by Kuraray Co., Ltd., Kuraray Poval LM-20SO (degree of saponification = 40%) manufactured by Kuraray Co., Ltd. Polymerization degree = 2,000), Gohsenol NM-14 manufactured by Nippon Synthetic Chemical Industry Co., Ltd. (degree of saponification = 99%, degree of polymerization = 1,400) and the like can be used.

As alkoxysilane, the general formula:
R _1n Si (OR ₂ ) _m
(In the formula, R ₁ and R ₂ each independently represent an organic group having 1 to 8 carbon atoms, n represents an integer of 0 or more, m represents an integer of 1 or more, and n + m represents an Si atom. Can be suitably used. In the above formula, specific examples of the organic group represented by R ₁ include, for example, methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, sec-butyl group. , T-butyl group, n-hexyl group, n-octyl group, and other alkyl groups. Specific examples of the alkoxysilane include, for example, tetramethoxysilane: Si (OCH ₃ ) ₄ , tetraethoxysilane: Si (OC ₂ H ₅ ) ₄ , tetrapropoxysilane: Si (OC ₃ H ₇ ) ₄ , tetrabutoxysilane. : Si (OC ₄ H ₉ ) ₄ or the like can be used.

  The above-mentioned water-soluble polymer and alkoxysilane are mixed, and a solution to which a sol-gel method catalyst, water, and an organic solvent are added as desired is applied to the surface of a thin film made of aluminum oxide or silicon oxide. By condensation, a gas barrier coating film can be formed. In the present invention, a composite polymer layer in which two or more of the above-described coating films are stacked may be formed on a thin film made of aluminum oxide or silicon oxide.

  Moreover, in this invention, a silane coupling agent can be added to said coating liquid for gas barrier coating-film formation, The gas barrier coating film obtained by this is especially preferable. As the silane coupling agent, known organic reactive group-containing organoalkoxysilanes can be used. In particular, an organoalkoxysilane having an epoxy group is suitable, for example, γ-glycidoxypropyltrimethoxy. Silane, γ-glycidoxypropylmethyldiethoxysilane, β- (3,4-epoxycyclohexyl) ethyltrimethoxysilane, or the like can be used. The above silane coupling agents may be used alone or in combination of two or more. In this invention, the usage-amount of the above silane coupling agents can be used within the range of about 1-20 mass parts with respect to 100 mass parts of said alkoxysilane.

  As a coating method of the coating liquid for forming a gas barrier coating film, conventionally known means such as roll coating such as a gravure roll coater, spray coating, spin coating, dipping, brush, bar code, applicator and the like are used. . Although the thickness of the coating film varies depending on the type of the coating solution, the thickness after drying may be in the range of about 0.01 to 100 μm. However, if the thickness is 50 μm or more, the film is likely to crack. It is preferable to be set to ˜50 μm.

  As a sol-gel method catalyst for polycondensation with a coating solution, a tertiary amine that is substantially insoluble in water and soluble in an organic solvent is used. Specifically, for example, N, N-dimethylbenzylamine, tripropylamine, tributylamine, tripentylamine and the like can be used. In particular, N, N-dimethylbenzylamine is suitable, and 0.01 to 1.0 part by mass, especially about 0.03 part by mass is used per 100 parts by mass of the total amount of alkoxysilane and silane coupling agent. It is preferable to do.

  Moreover, an acid can also be used as a catalyst of a sol-gel method, for example, mineral acids, such as a sulfuric acid, hydrochloric acid, nitric acid, organic acids, such as an acetic acid and tartaric acid, and others can be used. The amount of the acid used is preferably about 0.001 to 0.05 mol, particularly about 0.01 mol, relative to the total molar amount of alkoxysilane and the alkoxysilane content (for example, silicate moiety) of the silane coupling agent.

  Water contained in the coating solution is added in a proportion of 0.1 to 100 mol, preferably 0.8 to 2 mol, per 1 mol of the total molar amount of the solution alkoxide. Moreover, it is preferable that the polyvinyl alcohol and the ethylene-vinyl alcohol copolymer contained in the coating liquid for forming a gas barrier coating film are in a state dissolved in a coating liquid containing the above alkoxysilane, silane coupling agent, and the like. Therefore, an organic solvent may be appropriately selected and added. For example, as the organic solvent, methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, n-butanol and the like can be used.

  In general, the thickness of the gas barrier layer is preferably 0.01 to 50 μm, more preferably 1 to 10 μm, from the viewpoint of gas barrier properties and transparency.

Ultraviolet absorbing layer In the present invention, the ultraviolet absorbing layer contains an ultraviolet absorber and a fluorescent brightening agent. When the ultraviolet absorbing layer contains the ultraviolet absorber and the fluorescent brightening agent in combination, the light transmittance at each wavelength of the medical transparent packaging material can be adjusted within a desired range. Ultraviolet absorbing agent is preferably, and more preferably ranges addition of 0.55~0.8g / ^{m 2} to so as to be contained in the ultraviolet absorbing layer in a proportion ranging from 0.5~0.8g / ^{m 2} Is. The fluorescent brightening agent is preferably so as to be contained in the ultraviolet absorbing layer in a proportion ranging from 0.1 to 0.8 g / ^{m 2,} the range further to 0.2-0.5 g / ^{m 2} Is more preferable. The ultraviolet absorbing layer may further contain a coloring material. Colorant is preferably so as to be contained in the ultraviolet absorbing layer in a proportion ranging from 0.01g~2g / ^{m 2,} those more preferably in a range more of 0.05g~0.8g / ^{m 2} .

  As the ultraviolet absorber, at least one selected from the group consisting of a benzophenone ultraviolet absorber, a benzotriazole ultraviolet absorber, a salicylate ultraviolet absorber, a triazine ultraviolet absorber, and a benzoate ultraviolet absorber is used. It is preferable to use a triazine-based ultraviolet absorber.

  Examples of triazine ultraviolet absorbers include hydroxyphenyl triazine, 2,4-bis [2-hydroxy-4-butoxyphenyl] -6- (2,4-dibutoxyphenyl) -1,3-5-triazine, and hydroxy Examples thereof include at least one selected from the group consisting of phenyltriazine-based aqueous dispersions.

  Examples of the benzophenone ultraviolet absorber include 2-hydroxybenzophenone, 2,4-dihydroxybenzophenone, 2,2′-dihydroxy-4,4′-dimethoxybenzophenone, 2,2′-4,4′-tetrahydroxybenzophenone, 2 -Hydroxy-4-methoxybenzophenone, hydroxymethoxybenzophenonesulfonic acid and its trihydrate, and at least one selected from the group consisting of sodium hydroxymethoxybenzophenonesulfonate.

  Examples of the benzotriazole ultraviolet absorber include 2- (5-methyl-2-hydroxyphenyl) benzotriazole, 2- (2′-hydroxy-5′-t-octylphenyl) benzotriazole, and 2- (2H-benzo And at least one selected from the group consisting of triazol-2-yl) -6- (1-methyl-1-phenylethyl) -4- (1,1,3,3-tetramethylbutyl) phenol.

  Examples of the salicylate-based ultraviolet absorber include at least one selected from the group consisting of phenyl salicylate, 4-methylphenyl salicylate, 4-t-butylphenyl salicylate, and 2-ethylhexyl salicylate.

  Examples of the benzoate ultraviolet absorber include 2,4-di-tert-butylphenyl-3,5-di-tert-butyl-4-hydroxybenzoate.

  As the optical brightener, it is preferable to use at least one selected from the group consisting of a diaminostilbene fluorescent brightener, a bis-stynylbiphenyl fluorescent brightener, and a benzoxazolylthiophene fluorescent brightener. . Examples of the diaminostilbene fluorescent whitening agent include FWA-1 (Disodium 4,4′-bis [(4-anilino-6-morpholino-1,3,5-triazin-2-yl) amino) stilbene-2, 2'-disulphonate: CAS No. 16090-02-1). Examples of the bisstyryl biphenyl fluorescent whitening agent include FWA-5 (Benzenesulfonic acid, 2,2 ′-([1,1′-biphenyl] -4,4′-diyldi-2,1-ethylenediyl) bis-, disodium salt; CAS No. 27344-41-8). Examples of the benzoxazolylthiophene fluorescent brightening agent include (2,5 bis (5-ter-butyl-2-benzoxazolyl) thiophenone. From the viewpoint of safety, FWA-1 and FWA It is preferable to use -5.

  As the colorant, it is preferable to use pigments such as white, red, yellow, blue, and black. By adding such a colorant, it is possible to cause a change in color tone and specific wavelength absorptivity in appearance in addition to the color shift by the fluorescent whitening agent. Further, in addition to the improvement of physical properties such as specific wavelength absorption, it is also effective for design discrimination for articles added with a fluorescent brightening agent.

  The ultraviolet absorbing layer can be formed by applying an ink in which the above-described ultraviolet absorbing agent, fluorescent whitening agent, and colorant are dispersed in an adhesive or the like. As the adhesive, conventionally known laminating adhesives such as one-pack or two-pack curable or non-cured vinyl, (meth) acrylic, polyamide, polyester, polyether, polyurethane, Epoxy-based, rubber-based and other solvent-type, aqueous-type, or emulsion-type adhesives for laminating can be used. Examples of the coating method for the adhesive include a direct gravure roll coating method, a gravure roll coating method, a kiss coating method, a reverse roll coating method, a fountain method, a transfer roll coating method, and other methods. Usually, the thickness of the ultraviolet absorbing layer is preferably 1 to 20 μm, more preferably 1 to 10 μm, from the viewpoint of ultraviolet blocking properties and transparency.

Adhesive layer In the present invention, the adhesive layer is not particularly limited, but can be formed using a resin having thermal adhesiveness. Specifically, as the resin having thermal adhesiveness, for example, low density polyethylene resin, medium density polyethylene resin, high density polyethylene resin, linear low density polyethylene resin, ethylene-α polymerized using a metallocene catalyst Copolymer resin with olefin, ethylene-polypropylene copolymer resin, ethylene-vinyl acetate copolymer resin, ethylene-acrylic acid copolymer resin, ethylene-ethyl acrylate copolymer resin, ethylene-methacrylic acid copolymer Combined resin, ethylene-methyl methacrylate copolymer resin, ethylene-maleic acid copolymer resin, ionomer resin, polyolefin resin with unsaturated carboxylic acid, unsaturated carboxylic acid, unsaturated carboxylic acid anhydride, ester monomer Graft polymerization or copolymerization resin, maleic anhydride is added to polyolefin resin. It can be used a graft modified resin or the like. These materials can be used alone or in combination. Usually, the thickness of the adhesive layer is preferably in the range of 1 to 100 μm, and more preferably in the range of 1 to 20 μm, from the viewpoints of moldability and transparency.

  EXAMPLES Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples, but the present invention is not construed as being limited to the contents of the following examples.

Example 1
A polyethylene terephthalate film (PET) having a thickness of 12 μm was prepared as a base material for producing a medical packaging material . Silicon oxide was deposited on one surface of the substrate to form a silicon oxide deposited film.

Next, according to the composition shown below, an ethyl silicate 40, isopropyl alcohol, acetylacetone of composition (b) prepared in advance in an EVOH solution dissolved in a mixed solvent of EVOH, isopropyl alcohol, and ion-exchanged water of composition (a) A hydrolyzed liquid composed of aluminum and ion-exchanged water was added and stirred, and a liquid mixture composed of a polyvinyl alcohol aqueous solution having a composition (c) prepared in advance, acetic acid, isopropyl alcohol and ion-exchanged water was added and stirred, and colorless and transparent A composition for forming a barrier coating film was obtained.
Composition for forming a barrier coating film
a EVOH (ethylene copolymerization ratio 29%) 0.122% by mass
b Ethylsilicate 40 (Colcoat Co.) 9.146% by mass
c Polyvinyl alcohol 1.220% by mass
Subsequently, a gas barrier coating film was formed by applying a barrier coating film-forming composition having the above composition on the silicon oxide vapor deposition film to form a gas barrier layer.

On the other hand, a polyethylene film (PE) having a thickness of 40 μm was prepared as an adhesive layer. An ink (Tokyo Ink) containing a triazine ultraviolet absorber (BASF Japan Ltd .: TINUVIN 477) and a benzoxazolylthiophene fluorescent whitening agent (BASF: TINOPAL OB) on one surface of the adhesive layer. (Inc .: LG-UV series) and a polyether polyurethane adhesive (Daiichi Seika Kogyo Co., Ltd .: main component—Seikabond A-188, curing agent—two-component curing type using Seikabond C-89) Was applied to form an ultraviolet absorbing layer, and was then bonded to the gas barrier coating film. The ultraviolet absorbing layer is formed to a thickness of 3 μm by a dry laminating method using a gravure roll. The content of the ultraviolet absorber in the ultraviolet absorbing layer was 0.55 g / m ² . The content of the fluorescent brightening agent in the ultraviolet absorbing layer was set to 0.3 g / m ² . The medical transparent packaging material was produced by the above.

Comparative Example 1
A transparent medical packaging material was prepared in the same manner as in Example 1 except that the triazine ultraviolet absorber and the fluorescent brightening agent were not added to the ultraviolet absorbing layer.

Comparative Example 2
A medical packaging material (opaque) was produced in the same manner as in Example 1 except that an aluminum vapor deposition film was provided instead of the silicon oxide vapor deposition film in the gas barrier layer.

Evaluation of performance of medical packaging material The thermal transfer foil prepared above was evaluated for (1) light transmittance, (2) water vapor transmission rate, (3) color difference after storage test, and (4) visibility. .

(1) Measurement of light transmittance The light transmittance at each wavelength of 380 nm, 400 nm, and 600 nm was measured for the medical packaging material produced above. The light transmittance was measured using UV-2400PC (manufactured by Shimadzu Corporation) in accordance with JIS-K7105.

(2) Measurement of water vapor transmission rate The water vapor transmission rate was measured about the medical packaging material produced above. The water vapor transmission rate was measured using PERMATRAN-W (manufactured by Mocon) in accordance with “moisture permeability test method” (conditions: 40 ° C., 90% RH) of JIS standard Z-0208 or 0222.

(3) Measurement of color difference after storage test The medical solution was put into the medical packaging material prepared above and stored for 14 days at 20 cm just below the chemical lamp. Thereafter, the chemical solution in the chemical solution container is taken out and the difference in absorbance at all wavelengths in the visible light region (value after storage-value immediately before storage) is calculated using a spectrocolorimeter CLR-7100F (manufactured by Shimadzu Corporation). The color difference was measured. The measurement conditions were transmitted light and a D65 / 10 degree field of view. Further, physiological saline was used for standard calibration.

(4) Evaluation of visibility Pharmaceuticals were packaged using the medical packaging material produced above. About the pharmaceutical after packaging, the visibility of the contents was judged visually. The evaluation criteria are as follows.
Evaluation criteria : ○: The contents could be discriminated.
-X: The contents could not be identified.

The results of the above evaluation are shown in Table 1. The medical transparent packaging material satisfying the composition of the present invention has excellent visible light permeability and excellent water vapor barrier properties while sufficiently blocking ultraviolet rays. Moreover, it was possible to achieve both prevention of light deterioration of the contents and ensuring of the visibility of the contents.

DESCRIPTION OF SYMBOLS 10 Medical transparent packaging material 20 Base material layer 30 Gas barrier layer 40 Ultraviolet absorption layer 50 Adhesive layer

Claims (12)

A transparent packaging material for medical use comprising a base material layer, a gas barrier layer containing silicon oxide, an ultraviolet absorbing layer, and an adhesive layer in this order,
The ultraviolet absorbing layer comprises an ultraviolet absorber and an optical brightener;
The ultraviolet absorber is a triazine-based ultraviolet absorber;
The fluorescent brightener is at least one selected from the group consisting of a diaminostilbene fluorescent brightener, a bisstyryl biphenyl fluorescent brightener, and a benzoxazolylthiophene fluorescent brightener;
The medical transparent packaging material has a light transmittance at a wavelength of 380 nm of 20% or less, a light transmittance at a wavelength of 400 nm of 20% or less, and a light transmittance at a wavelength of 600 nm of 60% or more. Packaging material.   The said medical transparent packaging material is 7% or less of light transmittance of wavelength 380nm, 7% or less of light transmittance of wavelength 400nm, and light transmittance of wavelength 600nm is 70% or more. Transparent packaging material for medical use as described in 1. The medical transparent packaging material according to claim 1 or 2, wherein the water vapor permeability of the medical transparent packaging material is 0.5 g / (m ² · day) or less. The triazine-based ultraviolet absorber is hydroxyphenyl triazine, 2,4-bis [2-hydroxy-4-butoxyphenyl] -6- (2,4-dibutoxyphenyl) -1,3-5-triazine, and hydroxy The medical transparent packaging material according to any one of claims 1 to 3 , which is at least one selected from the group consisting of phenyltriazine-based aqueous dispersions. The medical transparent packaging material according to any one of claims 1 to 4 , wherein the ultraviolet absorbing layer further comprises a coloring material. The medical transparent packaging material according to any one of claims 1 to 5 , wherein the gas barrier layer is formed by providing a gas barrier coating film on a silicon oxide vapor deposition film. The medical transparent packaging material according to any one of claims 1 to 6 , wherein the medical transparent packaging material does not include an aluminum metal foil and / or an aluminum deposited film. The medical transparent packaging material according to any one of claims 1 to 7 , which is used as a pharmaceutical packaging material. The medical transparent packaging material according to any one of claims 1 to 7 , which is used as a packaging material for a medical device. The medical transparent packaging material according to any one of claims 1 to 7 , which is used as a packaging material for a pharmaceutical PTP. Used as an exterior material of a liquid formulation, medical transparent packaging material according to any one of claims 1-7. The medical transparent packaging material according to claim 11 , wherein the liquid preparation is an infusion bag or a prefilled syringe.

Images